This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Ocular Drug Therapies / Oral Delivery of Macromolecules
October 26-27, 2022 | 2-Day Digital Conference
Digital Conference8:00AM EST // 1:00PM BST // 2:00PM CEST
Menu

D. Scott Edwards
Chief Development Operating Officer at OcuTerra Therapeutics, Inc., USA
Speaker

Agenda Sessions

  • OTT166: A Small Molecule RGD-integrin Inhibitor for the Treatment of Diabetic Retinopathy

    12:05
    View Session

At this event

Prev
Next
John Gleeson
Senior Scientist - Biopharmaceutics
Merck & Co., USA

See D. Scott at Ocular Drug Therapies / Oral Delivery of Macromolecules